A European regulatory committee has rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially ...

Una comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer aprobado en Estados ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. | Eli Lilly is expanding its menu of ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...